Ergoferon and oseltamivir in treatment of influenza: Results of multicentre randomized comparative clinical trial

Antibiotiki i Khimioterapiya

Volumn 57, Issue 7-8, 2012, Pages 23-30

  Averyanov, A V ^a   Babkin, A P ^b   Bart, B Ya ^c   Volchetsky, A L ^h   Minina, E S ^d   Kozyrev, O A ^e   Kostinov, M P ^f   Petrov, D V ^g   Selkova, E P ^h   Putilovsky, M A ⁱ   Nechaev, V B ⁱ   Epstein, O I ⁱ   Andrianova, E N ⁱ  

^a FEDERAL BIOMEDICAL AGENCY OF RUSSIA   (Russian Federation)

^b VORONEZH STATE MEDICAL UNIVERSITY NAMED AFTER N N BURDENKO   (Russian Federation)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d OAO MOEK   (Russian Federation)

^e SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^f MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

^g YAROSLAVL STATE MEDICAL UNIVERSITY   (Russian Federation)

^h GN Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology   (Russian Federation)

ⁱ Materia Medica Holding   (Russian Federation)

Author keywords

Antiviral drugs; Ergoferon; Fever; Influenza; Release active antibodies

Indexed keywords

ANTIPYRETIC AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; GAMMA INTERFERON; HISTAMINE; OSELTAMIVIR;

ADOLESCENT; ADULT; BODY TEMPERATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; IMMUNOLOGY; INFLUENZA; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RUSSIAN FEDERATION; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIGENS, CD4; ANTIPYRETICS; ANTIVIRAL AGENTS; BODY TEMPERATURE; FEMALE; FEVER; HISTAMINE; HUMANS; INFLUENZA, HUMAN; INTERFERON-GAMMA; MALE; MIDDLE AGED; OSELTAMIVIR; RUSSIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

ANIMALIA; INFLUENZAVIRUS A;

EID: 84872553181     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. http://www.who.int/influenza
2. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)//Centers for Disease Control and Prevention (CDC), U. S. Department of Health and Human Services, Atlanta. Recommendations and Reports. 2011;60:1.
3. Influenza Antiviral Medications: A Summary for Clinicians, 2011-2012//Centers for Disease Control and Prevention (CDC), U. S. Department of Health and Human Services, Atlanta/August 30, 2011.
4. http://polit.ru/article/2011/02/07/pandemia
5. Tarasov S., Dugina Y., Sergeeva S., Epstein O. Oral antibody to interferon gamma in ultra low doses: clinical efficacy and interferon stimulation in patients with upper respiratory viral infections. Fundament Clin Pharmacol 2008;22:2:37-37.
6. Tarasov S. A., Zarubaev V. V., Gorbunov E. A. Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A (H1N1) 2009 virus infection in mice. Antiviral Res 2012;93(2):219-224.
7. Vasil'ev A. N., Sergeeva S. A., Kachanova M. V. Use of ultralow doses of antibodies to gamma-interferon in the treatment and prophylaxis of viral infections. Antibiot khimioter 2008;53:32-35.
8. Baccam P., Beauchemin C., Macken Ñ. A., Hayden F. G., Perelson A. S. Kinetics of influenza A virus infection in humans. J Virol 2006;80:7590-7599. (Pubitemid 44092580)
9. Ha Youn Lee, David J. Topham, Sung Yong Park et al. Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virology Inlu 2009;7151-7165.
10. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low-and high-risk patients. J Antimicrob Chemother 2010;65:2:ii11-24.
11. Jefferson Ò., Demicheli V., Heeks J., Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2000;2:CD001265.
12. Jefferson Ò., Jones M., Doshi P. et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: a Cochrane review. Cochrane Database Syst Rev 2010 Feb. 17;2:CD001265.
13. Shishkina L. N., Skamovich M. O., Kabanov A. S. et al. Antiviral activity of anaferon (pediatric formulation) in mice infected with pandemic influenza virus A (H1N1/09). Bull Exp Biol Med 2010;149, 612-614.
14. Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother 2009;64:1:1-4.
15. Sanders C. J., Doherty P. C., Thomas P. O. Respiratory epithelial cells in innate immunity to influenza virus infection. Cell Tissue Res 2011;343:13-21.
16. To AT., Hung I. F., Li I. W. et al. Delayed clearance of viral load, marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010;50:850-859.